Infectious Disease ·
Review examines β-lactams targeting carbapenemase-producing Enterobacterales
A review in *Clinical Microbiology Reviews* surveys recently approved and investigational β-lactams and β-lactam/β-lactamase inhibitor combinations active against carbapenemase-producing Enterobacterales. It discusses their activity against different carbapenemase classes and resistance mechanisms that could limit effectiveness.
- Reviews agents targeting carbapenem-resistant Enterobacterales.
- Covers cefiderocol and several inhibitor classes.
- Discusses activity and emerging resistance mechanisms.
Carbapenemase-producing Enterobacterales (CPE) are a major challenge for antimicrobial treatment because enzymes such as KPC, OXA-48-like, NDM, VIM and IMP can compromise carbapenems. This review provides a microbiological overview of recently approved and investigational agents developed to address carbapenem-resistant Enterobacterales; it does not report a new clinical trial or patient sample size.
The authors discuss cefiderocol and β-lactam combinations using several inhibitor classes, including penicillin-based sulfone derivatives, diazabicyclooctanes and cyclic boronates. The review covers inhibitor spectra, mechanisms of activity, findings from isogenic strains and collections of clinical Enterobacterales isolates, and emerging resistance mechanisms.
The article focuses on microbiology and drug mechanisms rather than comparative clinical outcomes. Its discussion may help frame therapeutic positioning and antimicrobial development, but the supplied abstract does not establish clinical efficacy or provide evidence for a change in treatment practice.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Clinical Microbiology Reviews: Innovative β-lactams and β-lactam/β-lactamase inhibitor combinations against carbapenemase-producing Enterobacterales ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.